Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery.

Détails

Ressource 1Télécharger: BIB_490395AE4FDF.P001.pdf (118.88 [Ko])
Etat: Public
Version: Final published version
ID Serval
serval:BIB_490395AE4FDF
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery.
Périodique
The oncologist
Auteur⸱e⸱s
Tejpar S., Bertagnolli M., Bosman F., Lenz H.J., Garraway L., Waldman F., Warren R., Bild A., Collins-Brennan D., Hahn H., Harkin D.P., Kennedy R., Ilyas M., Morreau H., Proutski V., Swanton C., Tomlinson I., Delorenzi M., Fiocca R., Van Cutsem E., Roth A.
ISSN
1549-490X (Electronic)
ISSN-L
1083-7159
Statut éditorial
Publié
Date de publication
2010
Peer-reviewed
Oui
Volume
15
Numéro
4
Pages
390-404
Langue
anglais
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Résumé
The number of agents that are potentially effective in the adjuvant treatment of locally advanced resectable colon cancer is increasing. Consequently, it is important to ascertain which subgroups of patients will benefit from a specific treatment. Despite more than two decades of research into the molecular genetics of colon cancer, there is a lack of prognostic and predictive molecular biomarkers with proven utility in this setting. A secondary objective of the Pan European Trials in Adjuvant Colon Cancer-3 trial, which compared irinotecan in combination with 5-fluorouracil and leucovorin in the postoperative treatment of stage III and stage II colon cancer patients, was to undertake a translational research study to assess a panel of putative prognostic and predictive markers in a large colon cancer patient cohort. The Cancer and Leukemia Group B 89803 trial, in a similar design, also investigated the use of prognostic and predictive biomarkers in this setting. In this article, the authors, who are coinvestigators from these trials and performed similar investigations of biomarker discovery in the adjuvant treatment of colon cancer, review the current status of biomarker research in this field, drawing on their experiences and considering future strategies for biomarker discovery in the postgenomic era.

Mots-clé
Biomarkers, Tumor, Chemotherapy, Adjuvant, Colorectal Neoplasms/genetics, Colorectal Neoplasms/pathology, Colorectal Neoplasms/therapy, Disease Progression, Genes, p53/genetics, Genomic Instability, Genomics, Humans, Microsatellite Instability, Phenotype, Predictive Value of Tests, Prognosis, Proto-Oncogene Proteins/genetics, Proto-Oncogene Proteins B-raf/genetics, Proto-Oncogene Proteins p21(ras), ras Proteins/genetics
Pubmed
Web of science
Open Access
Oui
Création de la notice
16/07/2010 14:28
Dernière modification de la notice
20/08/2019 13:56
Données d'usage